ArticleWorld journal of clinical cases2023
Successful treatment of lichen amyloidosis coexisting with atopic dermatitis by dupilumab: Four case reports.
Article in World journal of clinical cases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Rapid clinical response to nemolizumab in a patient with lichen amyloidosis.JAAD case reports · 2026Article
- Remission of lichen amyloidosis achieved with upadacitinib: A case report.JAAD case reports · 2025Article
- Nemolizumab for treatment of lichen amyloidosis.JAAD case reports · 2025Article
- Dupilumab for treatment of primary cutaneous amyloidosis in adults: two case reports and literature review.Frontiers in medicine · 2025Article
- Improvement of Low-Dose Abrocitinib-Resistant Lichen Amyloidosis with Dupilumab: Two Case Reports.Clinical, cosmetic and investigational dermatology · 2025Article
- Endocrine Perspective of Cutaneous Lichen Amyloidosis:Clinics and practice · 2024Article
- Lichen Amyloidosis in an Atopic Patient Treated with Dupilumab: A New Therapeutic Option.Diseases (Basel, Switzerland) · 2024Article
- Case report: Abrocitinib: a potential therapeutic option for lichen amyloidosis associated with atopic dermatitis.Frontiers in immunology · 2024Article
- Remission of refractory lichen amyloidosis with baricitinib.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLichen amyloidosis (LA) is a chronic, severely pruritic skin disease, which is the most common form of primary cutaneous amyloidosis. The treatment of LA has been considered to be difficult. LA may be associated with atopic dermatitis (AD), and in this setting, the treatment options may be more limited. Herein, we report four cases of LA associated with AD successfully treated by dupilumab. CASE SUMMARY: In this article, we describe four cases of patients who presented with recurrent skin rash accompanied by severe generalized intractable pruritus, diagnosed with refractory LA coexisting with chronic AD. Previous treatments had not produced any apparent improvement. Thus, we administered dupilumab injection subcutaneously at a dose of 600 mg for the first time and 300 mg every 2 wk thereafter. Their lesions all markedly improved.
conclusionDupilumab may be a new useful treatment for LA coexisting with AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.